News | March 01, 2024
Pfizer Oncology hosts innovation day
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Study achieves primary endpoint of radiographic progression-free survival
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
